Truist Financial Cuts Hims & Hers Health (NYSE:HIMS) Price Target to $33.00

Hims & Hers Health (NYSE:HIMS) had its target price trimmed by Truist Financial from $39.00 to $33.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a hold rating on the stock.

Other equities analysts also recently issued reports about the company. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Canaccord Genuity Group raised their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Finally, Leerink Partners lifted their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $38.25.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $27.13 on Thursday. Hims & Hers Health has a one year low of $11.20 and a one year high of $72.98. The firm has a market capitalization of $6.03 billion, a P/E ratio of 61.66 and a beta of 1.65. The company’s fifty day moving average is $38.75 and its two-hundred day moving average is $30.37.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, sell-side analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 54,153 shares of Hims & Hers Health stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $29.90, for a total value of $1,619,174.70. Following the completion of the sale, the insider now owns 165,650 shares in the company, valued at $4,952,935. The trade was a 24.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the transaction, the chief executive officer now directly owns 97,687 shares of the company’s stock, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 835,884 shares of company stock valued at $31,659,701 over the last 90 days. Insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently made changes to their positions in HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter worth $28,000. Raleigh Capital Management Inc. increased its stake in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after purchasing an additional 1,413 shares during the period. Finally, Summit Securities Group LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.